Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
McKesson
Mallinckrodt
Moodys
Fuji
Merck
Chubb
UBS
Covington

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,408,893

« Back to Dashboard

Which drugs does patent 9,408,893 protect, and when does it expire?

Patent 9,408,893 protects ADLYXIN and is included in one NDA.

This patent has eighteen patent family members in twenty countries.
Summary for Patent: 9,408,893
Title:Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
Abstract: The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.
Inventor(s): Niemoeller; Elisabeth (Frankfurt am Main, DE), Muehlen-Bartmer; Isabel (Frankfurt am Main, DE), Silvestre; Louise (Paris, FR), Boka; Gabor (Paris, FR), Miossec; Patrick (Paris, FR)
Assignee: Sanofi-Aventis Deutschland GMBH (Frankfurt am Main, DE)
Application Number:13/595,590
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,408,893

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sanofi-aventis Us ADLYXIN lixisenatide SOLUTION;SUBCUTANEOUS 208471-001 Jul 27, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial COMBINATION TREATMENT WITH A GLITAZONE FOR IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS ➤ Try a Free Trial
Sanofi-aventis Us ADLYXIN lixisenatide SOLUTION;SUBCUTANEOUS 208471-002 Jul 27, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial COMBINATION TREATMENT WITH A GLITAZONE FOR IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,408,893

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
11179149Aug 29, 2011

International Patents Family Members for US Patent 9,408,893

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 087693 ➤ Try a Free Trial
Australia 2012300978 ➤ Try a Free Trial
Brazil 112014004726 ➤ Try a Free Trial
Canada 2846413 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Merck
Cerilliant
Federal Trade Commission
Accenture
Queensland Health
Medtronic
Fish and Richardson
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.